Skip to main content
SpringerLink
Log in

Angiotensin II Receptor Blockade Physiological and Clinical Implications

  • Book
  • © 1998

Overview

Editors:
  1. Naranjan S. Dhalla

    1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Peter Zahradka

    1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Ian M. C. Dixon

    1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  4. Robert E. Beamish

    1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Progress in Experimental Cardiology (PREC, volume 2)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (42 chapters)

  1. Front Matter

    Pages i-xliii
    Download chapter PDF

  2. Pharmacological Interruption of Renin-Angiotensin in Hypertension

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Pharmacological Interruption Of The Renin System And The Kidney: Lessons From Comparative Pharmacology

      • Norman K. Hollenberg
      Pages 3-13

    3. The Brain Renin-Angiotensin System And Salt-Sensitive Hypertension

      • Shereeni J. Veerasingham, Frans H.H. Leenen
      Pages 15-32

    4. At1 Angiotensin Receptor Blockade and Angiotensin Converting Enzyme Inhibition: Effects on Vascular Remodeling and Endothelial Dysfunction in Shr

      • Ernesto L. Schiffrin, Jin-S. Li, Ali M. Sharifi
      Pages 33-40

    5. Cellular Physiology of Angiotensin II Receptors in Vascular Smooth Muscle Cells

      • P. Zahradka, D. Wilson, L. Saward, L. Yau, P. K. Cheung
      Pages 41-50

    6. Angiotensin II Enhanced The Expression Of Inhibitory Guanine Nucleotide Regulatory Protein in Vascular Smooth Muscle Cells: Blockade By at1 Antagonist

      • Madhu B. Anand-Srivastava, Anuradha Palaparti
      Pages 51-64

    7. Comparison of the Inhibitory Actions of Angiotensin AT1 Receptor Antagonists in the Peripheral Vascular Bed

      • Hunter C. Champion, David G. Lambert, Trinity J. Bivalacqua, Dennis B. Mcnamara, Philip J. Kadowitz
      Pages 65-86

    8. Angiotensin II Receptor Antagonists in Patients With Renal Failure and on Hemodialysis

      • Donald Allan, Peter Bolli
      Pages 87-91

    9. The Place of Angiotensin II Antagonists in Relation to the Canadian Hypertension Society Guidelines

      • S. George Carruthers
      Pages 93-103

    10. Translating Clinical Guidelines For Management of Heart Failure and Hypertension Into Clinical Practice

      • Simon W. Rabkin
      Pages 105-113

    11. Cough Induced by Pharmacological ModulatiOn of the Renin-Angiotensin-Aldosterone System. Angiotensin Converting Enzyme Inhibitors And Angiotensin II Receptor Antagonists

      • Yves Lacourcière, Jean Lefebvre
      Pages 115-126

  3. Angiotensin Blockade and Cardiovascular Disease

    1. Front Matter

      Pages 127-127
      Download chapter PDF

    2. Angiotensin II Receptors AT1 and AT2: New Mechanisms of Signaling And Antagonistic Effects of AT1 and AT2

      • Tadashi Inagami, Satoru Eguchi, Satoshi Tsuzuki, Toshihiro Ichiki
      Pages 129-139

    3. Angiotensin Receptor Antagonists and Cardiovascular Remodeling

      • K. Sabri, C. Chassagne, B. Lévy, J.L. Samuel, L. Rappaport
      Pages 141-151

    4. Intersubject Variability in the Pharmacokinetics of Losartan

      • Jacques Turgeon
      Pages 153-161

    5. Functional Analysis of Tissue Renin-Angiotensin System Using “Gain and Loss of Function” Approaches: In Vivo Test of in Vitro Hypothesis

      • Ryuichi Morishita, Motokuni Aoki, Hidetsugu Matsushita, Shin-Ichiro Hayashi, Shigefumi Nakamura, Nobuaki Nakano et al.
      Pages 163-174

    6. Exploring the Difference Between Angiotensin Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists. A Focus on Bradykinin

      • Colin C. Barnes
      Pages 175-184

    7. Role of Cytokines in Septic Cardiomyopathy

      • Ursula Müller-Werdan, Heike Schumann, Ralph Fuchs, Harald Loppnow, Christopher Reithmann, Susann Koch et al.
      Pages 185-219

    8. In Pursuit of Optimal Care and Outcomes for Patients with Congestive Heart Failure: Insights from the Past Decade

      • Terrence Montague, Koon Teo, Laurel Taylor, Finlay McAlister, Margaret Ackman, Ross Tsuyuki
      Pages 221-232
Back to top

Keywords

About this book

The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio­ tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential.

Editors and Affiliations

  • Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish

Bibliographic Information

  • Book Title: Angiotensin II Receptor Blockade Physiological and Clinical Implications

  • Editors: Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish

  • Series Title: Progress in Experimental Cardiology

  • DOI: https://doi.org/10.1007/978-1-4615-5743-2

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1998

  • Hardcover ISBN: 978-0-7923-8147-1Published: 31 October 1998

  • Softcover ISBN: 978-1-4613-7631-6Published: 13 October 2012

  • eBook ISBN: 978-1-4615-5743-2Published: 06 December 2012

  • Series ISSN: 1389-1774

  • Edition Number: 1

  • Number of Pages: XLIII, 588

  • Topics: Cardiology

Publish with us

Policies and ethics

Back to top

Search

Navigation